Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

APCCC 2022 | Abiraterone for the treatment of cN1 prostate cancer

Darren Poon, MBChB, FRCR, FHKCR, FHKAM, The Chinese University of Hong Kong, Hong Kong, outlines data from the STAMPEDE study (NCT00268476), in which abiraterone was combined with androgen deprivation therapy (ADT) and radiotherapy for the treatment of high-risk locally advanced prostate cancer (including cN1 prostate cancer). This combination was shown to result in a significant improvement in patient outcomes when compared to ADT and radiotherapy alone. Dr Poon also discusses the consensus that this approach should be highly considered for treatment of high-risk locally advanced prostate cancer reached at the Advanced Prostate Cancer Consensus Conference (APCCC). This interview took place at the APCCC 2022 conference, held in Lugano, Switzerland.